Key Details
Annual ROE
-546.18%Annual Debt To Equity
-10.46Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 01, 2023Recent annual earnings:
Mar 01, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with EPZM included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Epizyme doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Epizyme?
- What is the ticker symbol for Epizyme?
- Does Epizyme pay dividends?
- What sector is Epizyme in?
- What industry is Epizyme in?
- What country is Epizyme based in?
- When did Epizyme go public?
- Is Epizyme in the S&P 500?
- Is Epizyme in the NASDAQ 100?
- Is Epizyme in the Dow Jones?
- When was Epizyme's last earnings report?
- When does Epizyme report earnings?
What is the primary business of Epizyme?
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
What is the ticker symbol for Epizyme?
The ticker symbol for Epizyme is NASDAQ:EPZM
Does Epizyme pay dividends?
No, Epizyme does not pay dividends
What sector is Epizyme in?
Epizyme is in the Healthcare sector
What industry is Epizyme in?
Epizyme is in the Biotechnology industry
What country is Epizyme based in?
Epizyme is headquartered in United States
When did Epizyme go public?
Epizyme's initial public offering (IPO) was on 31 May 2013
Is Epizyme in the S&P 500?
No, Epizyme is not included in the S&P 500 index
Is Epizyme in the NASDAQ 100?
No, Epizyme is not included in the NASDAQ 100 index
Is Epizyme in the Dow Jones?
No, Epizyme is not included in the Dow Jones index
When was Epizyme's last earnings report?
Epizyme's most recent earnings report was on 1 March 2023
When does Epizyme report earnings?
The date for Epizyme's next earnings report has not been announced yet